title: Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
abstract: Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in patients that had limited benefit from non-biologic systemic therapies and phototherapy. Despite standard-of-care systemic therapies being more likely to be cost-effective at this time, a Canadian cost-utility analysis found secukinumab to display benefit in quality-of-life gains in moderate-to-severe plaque psoriasis patients, and greater cost-effectiveness when compared to other biologic systemic therapies. Determination of the true economic value of secukinumab amongst the available therapies for moderate-to-severe plaque psoriasis will require continued economic evaluation.
authors.affiliation: a Faculty of Medicine, University of British Columbia , Vancouver , British Columbia , Canada.
authors.forename: Ian Ty
authors.initials: IT
authors.lastname: Wong
authors.affiliation: a Faculty of Medicine, University of British Columbia , Vancouver , British Columbia , Canada.
authors.forename: Kam
authors.initials: K
authors.lastname: Shojania
authors.affiliation: a Faculty of Medicine, University of British Columbia , Vancouver , British Columbia , Canada.
authors.forename: Jan
authors.initials: J
authors.lastname: Dutz
authors.affiliation: b Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver , British Columbia , Canada.
authors.forename: Nicole W
authors.initials: NW
authors.lastname: Tsao
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000068800:Etanercept / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D011788:Quality of Life; D012720:Severity of Illness Index; D000069549:Ustekinumab / Q000191:economics / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; C508717:IL17A protein, human; D020381:Interleukin-17; C555450:secukinumab; D000069549:Ustekinumab; D000068800:Etanercept
keywords: biologics; cost-effectiveness; economics; plaque psoriasis; secukinumab